• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Increased orexin levels linked with poor sleep quality in Alzheimer Disease

byAshley AaroeandJames Jiang
October 14, 2014
in Chronic Disease, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In Alzheimer disease (AD), increased cerebrospinal fluid (CSF) orexin levels were associated with diminished sleep quality, and increased cognitive decline.

2. CSF orexin levels appeared to be increased in patients with moderate-severe AD, as compared with healthy controls.

Evidence Rating Level: 3 (Average)

Study Rundown: Alzheimer disease (AD) is characterized by progressive loss of memory and executive function. A less discussed symptom of the disease is sleep dysregulation, which can have significant detrimental effects on quality of life. Sleep is also important for maintaining optimal cognition and memory consolidation. Essential to the regulation of sleep-wake cycles is a neurotransmitter called orexin A (or hypocretin 1), which increases arousal and wakefulness. This study recorded CSF orexin levels in 48 patients with AD and 29 age-matched controls, comparing these data points with metrics of sleep health.

Orexin was increased in patients with moderate to severe AD, and correlated with the number of tau proteins in the brain, which are the pathologic hallmarks of the disease. There also was a correlation between degree of cognitive impairment measured by the Mini Mental Status Exam (MMSE) and the severity of sleep dysfunction that patients experienced. The study therefore suggests that changes in the orexigenic system are involved in the pathogenesis of AD and result in these sleep disturbances. However, when all the patients with AD were pooled there was no significant difference in CSF orexin levels between them and controls, nor was there a difference between mild AD patients and the controls.

Click to read the study, published today in JAMA Neurology

Click to read an accompanying editorial in JAMA Neurology

RELATED REPORTS

Plasma p-tau217 is an accurate plasma biomarker of pathologic cerebral changes in patients with Down Syndrome

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Relevant Reading: Amyloid-β Dynamics are Regulated by Orexin and the Sleep-Wake Cycle

In-Depth [case-control study]: This study was performed in Italy. All subjects underwent history and physicals, neurologic examinations, neuropsychiatric evaluations, electroencephalogram, polysomnography, MRI of the brain, and lumbar puncture. AD patients were divided into two subgroups (mild, and moderate-severe) based on the severity of cognitive impairment measured by the MMSE. Serving as control patients were inpatients without dementia that underwent the above tests for other reason, such as suspected subarachnoid hemorrhage or polyneuropathy. Polysomnography was used to assess sleep quality, and the following variables were studied: time in bed, sleep onset latency, total sleep time, sleep efficiency, rapid eye movement (REM) sleep latency, REM sleep, and wakefulness after sleep onset.

CSF samples obtained by LP were analyzed for levels of amyloid beta1-42, t-tau, p-tau, and orexin. Patients with moderate-severe AD had higher mean orexin levels compared with controls (154.36 [SD 28.16] vs. 131.03 [SD 26.55]; P< 0.01) and worse quality sleep. For AD patients, levels of CSF orexin correlated directly with sleep onset latency (r=0.41; P=0.004) and stage 1 non-REM sleep (r=0.43; P=0.002). Moreover, CSF orexin levels were correlated with decreased sleep efficiency (r=−0.38; P=0.007), stage 3 non-REM sleep (r=−0.32; P=0.027), and REM sleep (r=−0.31; P=0.03). In the total AD cohort, orexin levels were correlated with total tau protein levels (r=0.32; P=0.03). There were no significant differences in orexin levels when comparing all patients with AD and controls.

More from this author: Glatiramer acetate (Copaxone) therapy may alter B cell function in multiple sclerosis, Dementia patients frequently on medications with minimal benefit, Walk test linked to quality of life in multiple sclerosis

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: Alzheimer’s diseaseorexin
Previous Post

Inconsistent quality of evidence for biomarker use on FDA drug labels

Next Post

2 Minute Medicine Rewind October 6 – October 13, 2014

RelatedReports

Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

Plasma p-tau217 is an accurate plasma biomarker of pathologic cerebral changes in patients with Down Syndrome

July 7, 2022
#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial
StudyGraphics

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

June 29, 2022
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress
Chronic Disease

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

June 17, 2022
Amyloid pathology may be detected decades prior to Alzheimer’s diagnosis
Chronic Disease

Rare APOE missense variants V236E and R251G associated with substantial reduction in risk of Alzheimer disease

June 2, 2022
Next Post
Esmolol-induced heart rate reduction may aid in septic shock

2 Minute Medicine Rewind October 6 – October 13, 2014

Tumor size, chemoembolization response may predict hepatocellular carcinoma recurrence

Optical molecular imaging improves lesion localization during liver procedures

Mortality after trauma increasingly due to preexisting conditions

Skilled nursing facility ratings linked to readmission and death rates

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Ciprofol comparable to propofol for general anesthesia induction for gynecological surgery
  • Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy
  • Type of compensation model influences gender pay gap in primary care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.